NEOVACCINE STRATEGIES
Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development. This technique, the passive administration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen.
NEOVACCINE STRATEGIES
Industry:
Biotechnology Life Science Pharmaceutical
Status:
Active
Total Funding:
74.67 K USD
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Neovaccine Strategies
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Neovaccine Strategies
More informations about "Neovaccine Strategies"
Neovaccine Strategies - Crunchbase Company Profile & Funding
Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse …See details»
Neovaccine Strategies - Funding, Financials, Valuation & Investors
Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa.See details»
Neovaccine Strategies
Neovaccine Strategies is developing a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Their technique generates antibodies to the abundant, highly …See details»
Vaccine Strategies - PMC
The new technologies of genomics, proteomics, and molecular immunology have led to an impressive increase in our knowledge of all aspects of virology, providing insights that can …See details»
Center for Cancer Vaccines | Dana-Farber Cancer Institute
The Center for Cancer Vaccines at Dana-Farber is dedicated to advancing cancer immunotherapy through vaccine development.See details»
Nanovaccine: an emerging strategy - PubMed
Subunit vaccines alone, however, fail to elicit sufficiently strong and long-lasting protective immunity against deadly pathogens. Nanoparticle (NP)-based delivery vehicles like …See details»
Neovaccine Strategies: 药物管线，专利，临床试验 - 智慧芽新药情 …
了解Neovaccine Strategies (Neovaccine Strategies)公司的药物管线，治疗领域，技术平台，以及它的。See details»
Strategies for Vaccination: Conventional Vaccine …
The initial strategy adopted for these novel vaccines was a DNA-based technique, which was subsequently followed by the development of viral vectors, including adeno-associated virus (AAV), lentiviral, or adenoviral vectors for vaccination, …See details»
Neoantigen Cancer Vaccines: Generation, Optimization, and …
This review aims to describe some of the key studies in the recent literature in this rapidly evolving field and summarize the current advances in neoantigen identification and selection, vaccine …See details»
Global estimates of rotavirus vaccine efficacy and effectiveness: a ...
Our approach enhances the understanding of global variation in rotavirus vaccine performance and can be used to inform predictions of the potential impact of rotavirus vaccines for …See details»
Immunization Agenda 2030 - World Health …
The World Health Assembly, with the support of countries and partners, has endorsed a new global vision and strategy, called the Immunization Agenda 2030 (IA2030), to address these challenges over the next decade and save over 50 …See details»
Neovaccine Strategies - Crunchbase
Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa.See details»
Strategies for Vaccination: Conventional Vaccine Approaches …
Jan 22, 2021 In this review, we describe conventional approaches to vaccine development, including strategies employing proteins, peptides, and attenuated or inactivated pathogens in …See details»
Grant - Neovaccine Strategies - 2019-01-09 - Crunchbase
Overview Edit Overview Section Organization Name Neovaccine Strategies Announced DateJan 9, 2019 Funding TypeGrant Money Raised obfuscated obfuscatedSee details»
Strategies for designing and optimizing new generation vaccines
Dec 1, 2001 Strategies are being developed to generate and mature autologous dendritic cells ex vivo to use as autologous vaccines for immunotherapy, or to expand dendritic cells in vivo …See details»
Burundi introduces malaria vaccine into routine immunization
Mar 17, 2025 Led by the Ministry of Health and with the support of Gavi, the Vaccine Alliance (Gavi), UNICEF, the World Health Organization (WHO), and Dalberg, Burundi has today …See details»
COVID-19 Vaccination Strategies and Their Adaptation to the …
Jun 6, 2022 In this conceptual, non-systematic review, we discuss vaccination strategies against COVID-19, focusing the attention on bottlenecks and hurdles that may jeopardize the …See details»
Gavi Board approves next five year strategy; outlines plans to …
Jun 7, 2024 The Gavi Board today approved the Vaccine Alliance’s strategy for the five-year period running from 2026 to 2030.See details»
Modifiable risk factors of vaccine hesitancy: insights from a mixed ...
Mar 12, 2025 Background Vaccine hesitancy, the delay in acceptance or reluctance to vaccinate, ranks among the top threats to global health. Identifying modifiable factors …See details»
Corruption risks in COVID-19 vaccine deployment: lessons learned …
Mar 7, 2025 Background During the COVID-19 pandemic corruption risks were amplified in health systems globally, increasing health inequities within and between countries. During the …See details»